NCT07351669 A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
| NCT ID | NCT07351669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongda Hospital |
| Condition | HCC - Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 121 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 121 participants in total. It began in 2026-01-20 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. age 18-75 years; 2. diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria; 3. Barcelona Clinic Liver Cancer (BCLC) stage A or B; 4. prior treatment with TACE; 5. undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE; 6. undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort); 7. informed consent. Exclusion Criteria: 1. contraindications to contrast-enhanced CT or MRI; 2. presence of extrahepatic malignancy; 3. poor image quality or incomplete clinical data; 4. lack of regular CT or MRI follow-up in non-surgical cohort; 5. withdrawal from the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07351669 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying HCC - Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07351669 currently recruiting?
Yes, NCT07351669 is actively recruiting participants. Contact the research team at shuhangzhang@outlook.com for enrollment information.
Where is the NCT07351669 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07351669 clinical trial?
NCT07351669 is sponsored by Zhongda Hospital. The trial plans to enroll 121 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.